CN117425668A - SARS-CoV-2病毒特异性滤泡辅助性T细胞Tfh - Google Patents

SARS-CoV-2病毒特异性滤泡辅助性T细胞Tfh Download PDF

Info

Publication number
CN117425668A
CN117425668A CN202280022066.3A CN202280022066A CN117425668A CN 117425668 A CN117425668 A CN 117425668A CN 202280022066 A CN202280022066 A CN 202280022066A CN 117425668 A CN117425668 A CN 117425668A
Authority
CN
China
Prior art keywords
seq
cov
sars
protein
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280022066.3A
Other languages
English (en)
Chinese (zh)
Inventor
山崎晶
陆修远
细野裕贵
石塚茂宜
山下和男
尼可拉·克劳德·保罗·萨克斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hongtai Biotechnology Co ltd
University of Osaka NUC
Original Assignee
Hongtai Biotechnology Co ltd
Osaka University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hongtai Biotechnology Co ltd, Osaka University NUC filed Critical Hongtai Biotechnology Co ltd
Publication of CN117425668A publication Critical patent/CN117425668A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • C07K16/104—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
CN202280022066.3A 2021-03-16 2022-03-15 SARS-CoV-2病毒特异性滤泡辅助性T细胞Tfh Pending CN117425668A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2021-042666 2021-03-16
JP2021042666 2021-03-16
PCT/JP2022/011707 WO2022196699A1 (ja) 2021-03-16 2022-03-15 ＳＡＲＳ－ＣｏＶ－２ウイルスに特異的な濾胞性ヘルパーＴ細胞（Ｔｆｈ）

Publications (1)

Publication Number Publication Date
CN117425668A true CN117425668A (zh) 2024-01-19

Family

ID=83322129

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280022066.3A Pending CN117425668A (zh) 2021-03-16 2022-03-15 SARS-CoV-2病毒特异性滤泡辅助性T细胞Tfh

Country Status (5)

Country Link
US (1) US20240309051A1 (https=)
EP (1) EP4310095A4 (https=)
JP (1) JPWO2022196699A1 (https=)
CN (1) CN117425668A (https=)
WO (1) WO2022196699A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024210175A1 (ja) * 2023-04-07 2024-10-10 国立大学法人大阪大学 濾胞性ヘルパーＴ細胞誘導性ＳＡＲＳ－ＣｏＶ－２スパイクタンパク質の部分ペプチド

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998037919A1 (en) 1997-02-28 1998-09-03 University Of Iowa Research Foundation USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
DK1005368T3 (da) 1997-03-10 2010-01-04 Ottawa Hospital Res Inst Anvendelse af nukleinsyrer, der indeholder ikke-metyleret CpG dinukleotid i kombination med alun som hjælpestoffer
EP1003531B1 (en) 1997-05-20 2007-08-22 Ottawa Health Research Institute Processes for preparing nucleic acid constructs
EP1003850B1 (en) 1997-06-06 2009-05-27 The Regents of the University of California Inhibitors of dna immunostimulatory sequence activity
AU1145699A (en) 1997-09-05 1999-03-22 Smithkline Beecham Biologicals (Sa) Oil in water emulsions containing saponins
WO2017091729A1 (en) * 2015-11-23 2017-06-01 President And Fellows Of Harvard College Compositions and methods for modulating an immune response
EP3476396A1 (en) * 2017-10-31 2019-05-01 Institut Gustave Roussy Bacterial and cell compositions for the treatment of colorectal cancer and methods for assessing a prognosis for patients having the same
TWI822726B (zh) * 2018-02-26 2023-11-21 德商梅迪基因免疫治療公司 Ｎｙｅｓｏ ｔ細胞受體
GB202011652D0 (en) * 2020-07-28 2020-09-09 Univ Oxford Innovation Ltd Polypeptide panels and uses thereof
KR20230117385A (ko) * 2020-12-04 2023-08-08 퀴아젠 사이언시스, 엘엘씨 SARS-CoV-2 (COVID-19)를 진단하고 SARS-CoV-2-특이적면역 기억을 모니터링하기 위한 조성물 및 방법

Also Published As

Publication number Publication date
EP4310095A4 (en) 2025-07-23
WO2022196699A1 (ja) 2022-09-22
EP4310095A1 (en) 2024-01-24
JPWO2022196699A1 (https=) 2022-09-22
US20240309051A1 (en) 2024-09-19

Similar Documents

Publication Publication Date Title
Tao et al. The biological and clinical significance of emerging SARS-CoV-2 variants
CN111560354B (zh) 重组新型冠状病毒及其制备方法和应用
EP4121104A2 (en) Coronavirus vaccines and methods of use
KR20230079259A (ko) Kras 돌연변이 특이적 t세포 수용체의 스크리닝 및 항종양 용도
KR20180033588A (ko) Ｇｉｔｒｌ 융합 단백질 및 그의 용도
CN111690050B (zh) 识别ebv-lmp2抗原的tcr及相应的核酸分子、载体、细胞和药物
US20240189416A1 (en) Stabilized coronavirus spike protein fusion proteins
CN118271460A (zh) 痘病毒多抗原嵌合疫苗及其用途
US11872276B2 (en) Zika virus chimeric polyepitope comprising non-structural proteins and its use in an immunogenic composition
CN115197331A (zh) 新冠病毒三聚体嵌合疫苗及其用途
CN114989308A (zh) 新冠病毒嵌合核酸疫苗及其用途
US20050221285A1 (en) Method for identifying or screening anti-viral agents
CN104955839A (zh) 对人偏肺病毒具有特异性的人抗体或其抗原结合性片段
CN117425668A (zh) SARS-CoV-2病毒特异性滤泡辅助性T细胞Tfh
US11819516B2 (en) Immunotherapy
CN113754740B (zh) 新型冠状病毒特异性抗原肽及其用途
CN115666633A (zh) CpG-佐剂的SARS-CoV-2病毒疫苗
JP5884100B2 (ja) 新型インフルエンザウイルス由来ヘマグルチニンタンパク質遺伝子を有するＤＩｓ株由来組換えワクシニアウイルス
CN116199766B (zh) 筛选tcr的方法及其分离的tcr
US20240159738A1 (en) Novel medical technique using follicular t-cells
EP3888677A1 (en) Strain dis-derived recombinant vaccinia virus having novel influenza virus-derived hemagglutinin protein gene
CN117903264B (zh) 新冠病毒SARS-CoV-2 HLA-A2限制性表位肽及应用
RU2848314C1 (ru) Профилактика и лечение бетакоронавируса
CN114751992B (zh) 一种冠状病毒的通用疫苗及其应用
US20240415905A1 (en) Medication for influenza

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination